The PIPE consists of common stock 

Davis Polk is advising the joint placement agents in connection with a private placement of $70 million of common stock of Korro Bio, Inc.

Korro intends to use the proceeds from the offering to fund the company’s operations, including development of pipeline product candidates, working capital and other general corporate purposes.

Headquartered in Cambridge, Massachusetts, Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Robert MacKenzie. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post